GSK PLCGSK PLCGSK PLC

GSK PLC

No trades
See on Supercharts

Key facts today

GSK will report Q3 results, projecting £8 billion in revenue, down from £8.15 billion last year, with net profit rising to £1.78 billion. A £1.8 billion charge for Zantac won't affect 2024 guidance.
GSK covers 80% of IDE275's global R&D costs. With the FDA approving IDEAYA Biosciences' new drug application for IDE275, GSK will receive a $7 million milestone payment.
GSK is identified as a major player in the RSV market, alongside Moderna and Pfizer, and is experiencing impacts from lower vaccination rates for RSV compared to the previous year.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪1.53 T‬MXN
‪104.05 B‬MXN
‪640.33 B‬MXN
‪2.04 B‬
Beta (1Y)
0.23

About GSK PLC ORD GBP0.3125


CEO
Emma N. Walmsley
Headquarters
London
Website
FIGI
BBG000BT3T60
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45
Yield to maturity
5.56%
Maturity date
Dec 18, 2045
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043
Yield to maturity
5.25%
Maturity date
Mar 18, 2043
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038
Yield to maturity
5.22%
Maturity date
May 15, 2038
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042
Yield to maturity
5.17%
Maturity date
Apr 10, 2042
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39
Yield to maturity
5.13%
Maturity date
Mar 9, 2039
G
XS217060907
GLAXOSM.CAP. MTN 20/35MTN
Yield to maturity
4.72%
Maturity date
May 12, 2035
G
72WI
GLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034
Yield to maturity
4.69%
Maturity date
Apr 15, 2034
G
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033
Yield to maturity
4.59%
Maturity date
Dec 19, 2033
G
US377373AH8
GLAXOSM.CAP. 19/29
Yield to maturity
4.56%
Maturity date
Jun 1, 2029
G
US377372AN7
GLAXOSMITHKLINE CAP.18/28
Yield to maturity
4.47%
Maturity date
May 15, 2028
G
GSK4632357
GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025
Yield to maturity
4.21%
Maturity date
May 15, 2025

Explore more bonds 

Curated watchlists where GSK/N is featured.